378 related articles for article (PubMed ID: 32241286)
1. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
[TBL] [Abstract][Full Text] [Related]
2. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
3. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model.
Chang KH; Wu YR; Chen YC; Chen CM
Brain Behav Immun; 2015 Feb; 44():121-7. PubMed ID: 25266150
[TBL] [Abstract][Full Text] [Related]
4. Altered sensory experience exacerbates stable dendritic spine and synapse loss in a mouse model of Huntington's disease.
Murmu RP; Li W; Szepesi Z; Li JY
J Neurosci; 2015 Jan; 35(1):287-98. PubMed ID: 25568121
[TBL] [Abstract][Full Text] [Related]
5. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.
Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ
Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313
[TBL] [Abstract][Full Text] [Related]
6. Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease.
Murmu RP; Li W; Holtmaat A; Li JY
J Neurosci; 2013 Aug; 33(32):12997-3009. PubMed ID: 23926255
[TBL] [Abstract][Full Text] [Related]
7. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.
Klapstein GJ; Fisher RS; Zanjani H; Cepeda C; Jokel ES; Chesselet MF; Levine MS
J Neurophysiol; 2001 Dec; 86(6):2667-77. PubMed ID: 11731527
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
10. Protein changes in synaptosomes of Huntington's disease knock-in mice are dependent on age and brain region.
Sapp E; Seeley C; Iuliano M; Weisman E; Vodicka P; DiFiglia M; Kegel-Gleason KB
Neurobiol Dis; 2020 Jul; 141():104950. PubMed ID: 32439598
[TBL] [Abstract][Full Text] [Related]
11. Motor skill learning modulates striatal extracellular vesicles' content in a mouse model of Huntington's disease.
Solana-Balaguer J; Garcia-Segura P; Campoy-Campos G; Chicote-González A; Fernández-Irigoyen J; Santamaría E; Pérez-Navarro E; Masana M; Alberch J; Malagelada C
Cell Commun Signal; 2024 Jun; 22(1):321. PubMed ID: 38863004
[TBL] [Abstract][Full Text] [Related]
12. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.
Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP
Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988
[TBL] [Abstract][Full Text] [Related]
13. Innate immune activation and aberrant function in the R6/2 mouse model and Huntington's disease iPSC-derived microglia.
Gasser J; Gillet G; Valadas JS; Rouvière L; Kotian A; Fan W; Keaney J; Kadiu I
Front Mol Neurosci; 2023; 16():1191324. PubMed ID: 37415834
[TBL] [Abstract][Full Text] [Related]
14. Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.
Crapser JD; Ochaba J; Soni N; Reidling JC; Thompson LM; Green KN
Brain; 2020 Jan; 143(1):266-288. PubMed ID: 31848580
[TBL] [Abstract][Full Text] [Related]
15. Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease.
Ragauskas S; Leinonen H; Puranen J; Rönkkö S; Nymark S; Gurevicius K; Lipponen A; Kontkanen O; Puoliväli J; Tanila H; Kalesnykas G
PLoS One; 2014; 9(12):e113317. PubMed ID: 25469887
[TBL] [Abstract][Full Text] [Related]
16. IKKβ slows Huntington's disease progression in R6/1 mice.
Ochaba J; Fote G; Kachemov M; Thein S; Yeung SY; Lau AL; Hernandez S; Lim RG; Casale M; Neel MJ; Monuki ES; Reidling J; Housman DE; Thompson LM; Steffan JS
Proc Natl Acad Sci U S A; 2019 May; 116(22):10952-10961. PubMed ID: 31088970
[TBL] [Abstract][Full Text] [Related]
17. Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice.
Bayram-Weston Z; Jones L; Dunnett SB; Brooks SP
Brain Res Bull; 2012 Jun; 88(2-3):104-12. PubMed ID: 21801812
[TBL] [Abstract][Full Text] [Related]
18. Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease.
Martín-Flores N; Pérez-Sisqués L; Creus-Muncunill J; Masana M; Ginés S; Alberch J; Pérez-Navarro E; Malagelada C
Cell Death Dis; 2020 Jul; 11(7):569. PubMed ID: 32732871
[TBL] [Abstract][Full Text] [Related]
19. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice.
Ransome MI; Hannan AJ
Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443
[TBL] [Abstract][Full Text] [Related]
20. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
Farrar AM; Callahan JW; Abercrombie ED
Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
